Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Itron Inc a un objectif de cours consensus de $111.47, basé sur les évaluations des 18 analystes. Le plus élevé est de $155 attribué par Guggenheim le juillet 14, 2025, et le plus bas est de $50 attribué par Morgan Stanley le novembre 4, 2022. Les 3 dernières évaluations d'analystes ont été publiées par JP Morgan, Roth Capital et JP Morgan le juillet 31, 2025, juillet 22, 2025 et juillet 22, 2025. Avec un objectif de cours moyen de $141 entre JP Morgan, Roth Capital et JP Morgan, il y a une variation implicite de 17.95% upside pour Itron Inc à partir de ces dernières évaluations d'analystes.
1calculé à partir des notes des analystes
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/31/2025 | 21.3% | JP Morgan | $128 → $145 | Upgrade | Neutral → Overweight | |||
07/22/2025 | 25.48% | Roth Capital | $130 → $150 | Maintains | Buy | |||
07/22/2025 | 7.08% | JP Morgan | $118 → $128 | Maintains | Neutral | |||
07/14/2025 | 29.66% | Guggenheim | $133 → $155 | Maintains | Buy | |||
05/05/2025 | 1.22% | Piper Sandler | $124 → $121 | Maintains | Neutral | |||
04/17/2025 | 11.26% | Guggenheim | $133 → $133 | Reiterates | Buy → Buy | |||
02/27/2025 | 11.26% | Guggenheim | $135 → $133 | Maintains | Buy | |||
02/27/2025 | 3.73% | Piper Sandler | $119 → $124 | Maintains | Neutral | |||
02/26/2025 | 10.42% | Canaccord Genuity | $130 → $132 | Maintains | Buy | |||
02/26/2025 | 9.59% | Oppenheimer | $124 → $131 | Maintains | Outperform | |||
11/06/2024 | 12.93% | Guggenheim | $128 → $135 | Maintains | Buy | |||
11/01/2024 | 13.77% | TD Cowen | $125 → $136 | Maintains | Buy | |||
11/01/2024 | 8.75% | Roth MKM | $125 → $130 | Maintains | Buy | |||
11/01/2024 | -0.45% | Piper Sandler | $110 → $119 | Maintains | Neutral | |||
11/01/2024 | 3.73% | Oppenheimer | $120 → $124 | Maintains | Outperform | |||
11/01/2024 | 10.42% | Baird | $123 → $132 | Maintains | Outperform | |||
09/27/2024 | 9.59% | Janney Montgomery Scott | → $131 | Initiates | → Buy | |||
08/21/2024 | 4.57% | Roth MKM | $125 → $125 | Maintains | Buy | |||
08/05/2024 | -7.98% | Stephens & Co. | $110 → $110 | Reiterates | Equal-Weight → Equal-Weight | |||
08/02/2024 | 4.57% | Roth MKM | $122 → $125 | Maintains | Buy | |||
08/02/2024 | 2.89% | Baird | $115 → $123 | Maintains | Outperform | |||
07/22/2024 | -7.98% | Piper Sandler | $109 → $110 | Maintains | Neutral | |||
07/17/2024 | -6.31% | Oppenheimer | $110 → $112 | Maintains | Outperform | |||
07/16/2024 | -6.31% | JP Morgan | $104 → $112 | Maintains | Neutral | |||
07/16/2024 | 2.06% | Roth MKM | $112 → $122 | Maintains | Buy | |||
07/11/2024 | 8.75% | Guggenheim | → $130 | Upgrade | Neutral → Buy | |||
06/20/2024 | 0.38% | Canaccord Genuity | $115 → $120 | Maintains | Buy | |||
05/21/2024 | -8.82% | Piper Sandler | $109 → $109 | Downgrade | Overweight → Neutral | |||
05/06/2024 | -7.98% | Stephens & Co. | $85 → $110 | Maintains | Equal-Weight | |||
05/03/2024 | -3.8% | Canaccord Genuity | $105 → $115 | Maintains | Buy | |||
05/03/2024 | -3.8% | TD Cowen | $110 → $115 | Maintains | Buy | |||
05/03/2024 | -6.31% | Roth MKM | $102 → $112 | Maintains | Buy | |||
05/03/2024 | -8.82% | Piper Sandler | $103 → $109 | Reiterates | Overweight → Overweight | |||
05/03/2024 | -7.98% | Oppenheimer | $100 → $110 | Maintains | Outperform | |||
04/23/2024 | -14.67% | Roth MKM | → $102 | Maintains | Buy | |||
04/11/2024 | -13.84% | Piper Sandler | $105 → $103 | Maintains | Overweight | |||
03/13/2024 | -7.98% | TD Cowen | $107 → $110 | Maintains | Outperform | |||
03/13/2024 | -3.8% | Baird | $108 → $115 | Maintains | Outperform | |||
03/13/2024 | -23.04% | JP Morgan | $77 → $92 | Maintains | Neutral | |||
02/27/2024 | -12.16% | Piper Sandler | $91 → $105 | Maintains | Overweight | |||
02/27/2024 | -9.65% | Baird | $68 → $108 | Upgrade | Neutral → Outperform | |||
01/19/2024 | -32.24% | Oppenheimer | → $81 | Upgrade | Perform → Outperform | |||
01/04/2024 | — | Raymond James | — | Downgrade | Outperform → Market Perform | |||
12/19/2023 | -23.87% | Piper Sandler | $72 → $91 | Upgrade | Neutral → Overweight | |||
12/12/2023 | -43.12% | JP Morgan | → $68 | Upgrade | Underweight → Neutral | |||
12/05/2023 | -31.4% | Roth MKM | → $82 | Initiates | → Buy | |||
12/01/2023 | -43.12% | Canaccord Genuity | → $68 | Initiates | → Hold | |||
11/03/2023 | -39.77% | Piper Sandler | $71 → $72 | Maintains | Neutral | |||
10/19/2023 | -45.62% | JP Morgan | $72 → $65 | Maintains | Underweight | |||
10/06/2023 | -40.61% | Piper Sandler | $63 → $71 | Maintains | Neutral | |||
09/22/2023 | -33.08% | Seaport Global | → $80 | Initiates | → Buy | |||
09/11/2023 | — | Guggenheim | — | Initiates | → Neutral | |||
08/18/2023 | -31.4% | Argus Research | → $82 | Upgrade | Hold → Buy | |||
08/04/2023 | -20.53% | TD Cowen | $85 → $95 | Maintains | Outperform | |||
08/04/2023 | -37.26% | Baird | $63 → $75 | Maintains | Neutral | |||
07/12/2023 | — | Raymond James | — | Downgrade | Strong Buy → Outperform | |||
05/08/2023 | -47.3% | Piper Sandler | $58 → $63 | Maintains | Neutral | |||
05/05/2023 | -41.44% | EF Hutton | $60 → $70 | Maintains | Buy | |||
05/05/2023 | -47.3% | Baird | $52 → $63 | Maintains | Neutral | |||
05/05/2023 | -41.44% | Raymond James | $60 → $70 | Maintains | Strong Buy | |||
03/03/2023 | -58.17% | JP Morgan | $53 → $50 | Downgrade | Neutral → Underweight | |||
02/28/2023 | -62.36% | Stephens & Co. | → $45 | Reiterates | → Equal-Weight | |||
02/28/2023 | -51.48% | Piper Sandler | $48 → $58 | Maintains | Neutral | |||
02/28/2023 | -56.5% | Baird | $40 → $52 | Maintains | Neutral | |||
02/28/2023 | -49.81% | EF Hutton | → $60 | Reiterates | → Buy | |||
02/28/2023 | -49.81% | Raymond James | $57 → $60 | Maintains | Strong Buy | |||
02/02/2023 | -39.77% | Cowen & Co. | $55 → $72 | Maintains | Outperform | |||
11/04/2022 | -58.17% | Morgan Stanley | $55 → $50 | Maintains | Equal-Weight | |||
11/04/2022 | -49.81% | EF Hutton | $72 → $60 | Maintains | Buy | |||
11/04/2022 | -52.32% | Raymond James | $68 → $57 | Maintains | Strong Buy | |||
10/20/2022 | -51.48% | JP Morgan | $65 → $58 | Maintains | Neutral |
Le dernier objectif de prix pour Itron (NASDAQ:ITRI) a été rapporté par JP Morgan le juillet 31, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $145.00 s'attendant à ce que ITRI se rise dans les 12 prochains mois (un possible changement de 21.30% upside). 17 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
La dernière note d'analyste pour Itron (NASDAQ:ITRI) a été fournie par JP Morgan, et Itron amélioré leur note overweight.
La dernière amélioration pour Itron Inc a eu lieu le juillet 31, 2025 lorsque JP Morgan a augmenté leur objectif de prix à $145. JP Morgan avait précédemment a neutral pour Itron Inc.
La dernière réduction pour Itron Inc a eu lieu le mai 21, 2024 lorsque Piper Sandler a changé leur objectif de prix de $109 à $109 pour Itron Inc.
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Itron, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Itron a été déposée le juillet 31, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers juillet 31, 2026.
Bien que les évaluations soient subjectives et changeront, la dernière note de Itron (ITRI) était un amélioré avec un objectif de prix de $128.00 à $145.00. Le prix actuel de Itron (ITRI) est de $119.54, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.